PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging readouts (i.e., WAT(Wave Analysis Technology) PET(Positron Emission Tomography)), after one or eight weeks of treatment. The effect of paroxetine alone after one or eight weeks of treatment will also be measured.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine; Vestipitant

Criteria

Inclusion criteria:

• Social phobic ambulatory subjects, defined according to DSM-IV criteria.

• Must be capable of giving informed consent and can comply with the study requirements.

• Women of childbearing potential must agree to acceptable method of birth control.

Exclusion criteria:

• Primary diagnosis within the past 6 months of other psychiatric conditions such as major depression or another anxiety disorder.

• Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type.

• Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months.

• Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine).

• Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG) findings.